KalVista changes fiscal year-end from April 30 to December 31

KalVista Pharmaceuticals, Inc.

Board approved change effective March 13, 2025; new fiscal year begins January 1, 2026.
Transition report on Form 10-KT will cover eight-month period May 1 through Dec 31, 2025.
During transition, a 10-Q for quarter ending July 31, 2025 will be filed, then quarters shift to Sept 30, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KalVista Pharmaceuticals, Inc.: The Company changed its fiscal year-end from April 30 to December 31 (effective 2025-03-13).

Change: fiscal year change
Effective: 2025-03-13

Exact text from the filing

On March 13, 2025, the Board of Directors of KalVista Pharmaceuticals, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from April 30 to December 31.

View on SEC.gov

Browse all governance changes →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-055602

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.